CD20 is a non-glycosylated phosphoprotein located on B cells. CD20 has been shown to be associated with a variety of other surface proteins on B cells (e.g. CD40, CD53, CD81 and CD82). It has been shown that some epigenetic factors (EZH2, HDAC1/2, HDAC6, Sin3A-HDAC1 complex) and transcription factors (USF, OCT1/2, PU.1, ELK1, PiP, ETS1, and SP1, NFκB, FOXO1, and SMAD2/3) can also regulate CD20 __expression__.
CD20 as a surface-specific molecular marker of human B-lymphocytes, functions an ideal target for the treatment of B-cell lymphoma. Importantly, there are more than 100 clinical trials for anti-CD20 monoclonal antibodies. Top players include Genmab, Amgen, Roche, Pfizer etc. Apparently, anti-CD20 monoclonal antibodies market is rapidly increasing and it is poised to grow by $9.05 bn during 2022-2026！(Read more about CD20)
To fully support researchers and pharmaceutical companies in their research on CD20 for the treatment of lymphoma, leukemia, autoimmune diseases, CUSABIO boasts CD20 active protein products (Code: CSB-MP015007HU) to assist you in your research on the mechanism of CD20 or its potential clinical value (Click to see a broad range of CD20-based products: Proteins; Antibodies; ELISAs).
Happy Valentines Day! CUSABIO appreciates the critical role that you and our products play in research since many scientists are diligently pursuing their research to further scientific innovation and discovery. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.
Kit
Protein
Antibody
Molecular Biology
CUSABIO TECHNOLOGY LLC
Postal Address: 7505 Fannin St Ste 610-322 Houston, TX 77054, USA
